Full history for every metric is available with a Kvantra account
Pharmiva AB (publ) (PHARM.ST)
Key financial summary
Financials in SEK| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | SEK m | - | - | 2 | 1 | 0 | 3 | 4 |
| Operating profit | SEK m | -24 | -21 | |||||
| Net profit | SEK m | - | - | -10 | -14 | -21 | -24 | -22 |
| EPS reported | SEK | -1.36 | -1.51 | |||||
| Operating cashflow per share | SEK | -1.31 | -1.31 | |||||
| Capex per share | SEK | 0.10 | 0.10 | |||||
| FCF per share | SEK | -1.41 | -1.41 | |||||
| Free cash flow | SEK m | -25 | -19 | |||||
| Net debt | SEK m | -14 | -5 | |||||
| Book value equity | SEK m | 27 | 15 | |||||
| Book value per share | SEK | 1.54 | 0.89 | |||||
| Number of shares | m | 17.38 | 17.38 | |||||
| DPS (TTM paid) | SEK | 0.00 | 0.00 |
Financial summary
Financials in SEK| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.04 | 0.84 | |||||
| P/S LTM | x | 10.58 | 3.51 | |||||
| P/FCF LTM | x | -1.13 | -0.67 | |||||
| EV/EBITDA LTM | x | -0.61 | -0.41 | |||||
| EV/Sales LTM | x | 5.20 | 2.17 | |||||
| Earnings Yield LTM | % | -85.16% | -243.32% | |||||
| FCF Yield | % | -88.20% | -149.64% | |||||
| Quality | ||||||||
| ROE | % | -88.23% | -82.12% | |||||
| ROIC | % | -88.20% | -88.20% | |||||
| Operating margin | % | -900.61% | -900.61% | |||||
| Gross margin | % | 98.40% | 98.40% | |||||
| FCF/Sales | % | -933.03% | -933.03% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +959.68% | +121.93% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | 0.63 | 0.63 | |||||
| EBIT/Net interest | x | -5,917.00 | -5,917.00 | |||||
| Net debt/market cap | % | -50.81% | -38.20% | |||||
| Net debt/Equity | x | -0.53 | -0.32 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
Pharmiva AB (publ), a Swedish company based in Lund, specializes in the research and development of medical products. Its flagship product is Vernivia, an over-the-counter vaginal mousse formulated for the treatment of bacterial vaginosis.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Pharmiva AB (publ) (PHARM.ST)
Pharmiva AB (publ), a Swedish company based in Lund, specializes in the research and development of medical products. Its flagship product is Vernivia, an over-the-counter vaginal mousse formulated for the treatment of bacterial vaginosis.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free